-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Enterprise News] Recently, listed companies are gradually disclosing their performance forecasts for the first half of 202 Among them, in the pharmaceutical equipment industry, there is also a company that firstly released an announcement of good results from January to June this year, namely Toffl.
Tofflon released the 2022 semi-annual performance forecast on July 1 It is estimated that from January 1, 2022 to June 30, 2022, the net profit attributable to shareholders of listed companies will be about 391 million to 425 million yuan, a year-on-year increase of 1 %~25%; after deducting non-recurring profit and loss, the profit was 362 million yuan – 396 million yuan, a year-on-year increase of 119% – 23
Regarding the reasons for the changes in performance, the company announced that: during the reporting period, the company focused on the development strategy of "systematization, internationalization, and digital intelligence" and the business goals set at the beginning of the year, and rationally allocated various resources to ensure the steady progress of the company's production and operation pl.
At the same time, the company actively overcame various difficulties under the epidemic environment in March, carried out production and manufacturing in an orderly manner, and actively took measures to reduce the adverse impact on the company's production and operati.
With the concerted efforts of all colleagues of the company, during the reporting period, the company's net profit attributable to shareholders of listed companies is expected to increase by 15%-25% compared with the same period of the previous ye.
The 2021 annual report shows that Tofflon is a comprehensive pharmaceutical equipment service provider that provides global pharmaceutical companies with overall solutions for pharmaceutical processes, core equipment and system engineeri.
After 28 years of hard work, more than 10,000 sets of pharmaceutical equipment and pharmaceutical manufacturing systems have served more than 2,000 global pharmaceutical companies in more than 40 countries and regions around the wor.
The company's main business is divided into three major sectors, namely pharmaceutical equipment sector, medical technology and technology sector, food equipment engineering sect.
As of the close on July 11, Tofflon closed at 33 yuan, down 83%, with a turnover rate of 51%, a trading volume of 65,600 lots, and a turnover of 219 million yu.
In terms of capital flow data, on July 11, the net outflow of main funds was 7649 million yuan, the net outflow of hot funds was 7398 million yuan, and the net inflow of retail funds was 5047 million yu.
It is worth mentioning that after Tofflon released the pre-announcement of its results for the first half of 2022, many institutions paid attenti.
Among them, Minsheng Securities released a research report on July 12, raising Tofflon's rating, and the rating was adjusted from "prudent recommendation" to "recommende.
Guosheng Securities gave Tofflon a rati.
It believes that the short-term impact of the epidemic will not constitute a restrictive factor on the company's annual performance, and Q3 is expected to usher in a full recovery; in the long run, the company is a platform supplier of domestic pharmaceutical equipment and consumabl.
Significant competitive advanta.
The agency said that it is optimistic about the company's firm strategy and forward-looking layo.
Taking advantage of the industry's momentum, the future can be expect.
1) Product perspective: The layout of equipment + consumables is complete, the equipment is the basic disk, and the consumables are expected to release increments in the future; 2) Rich customers: 30 years of deep cultivation in the pharmaceutical machine industry, with the help of rich customer resources, the trial and sales of products can be easily realized; 3 ) Internationalization: 11 new subsidiaries have been established in overseas countries and regions, and the CAGR of overseas revenue from 2015 to 2021 is 2
According to incomplete statistics, in the past 6 months, a total of 12 institutions of Tofflon have made predictions on its 2022 annual performan.
Among them, 5 institutions "buy", 3 institutions "increase", 2 institutions "recommend", 1 institution "prudently increase", and 1 institution "strongly recommend.
The target price forecast is 440 yu.
As of today's close, Tofflon's stock price fell 65%, with a turnover of 466 million, a turnover rate of 47%, and a price-earnings (TTM) of 28
Tofflon released the 2022 semi-annual performance forecast on July 1 It is estimated that from January 1, 2022 to June 30, 2022, the net profit attributable to shareholders of listed companies will be about 391 million to 425 million yuan, a year-on-year increase of 1 %~25%; after deducting non-recurring profit and loss, the profit was 362 million yuan – 396 million yuan, a year-on-year increase of 119% – 23
Regarding the reasons for the changes in performance, the company announced that: during the reporting period, the company focused on the development strategy of "systematization, internationalization, and digital intelligence" and the business goals set at the beginning of the year, and rationally allocated various resources to ensure the steady progress of the company's production and operation pl.
At the same time, the company actively overcame various difficulties under the epidemic environment in March, carried out production and manufacturing in an orderly manner, and actively took measures to reduce the adverse impact on the company's production and operati.
With the concerted efforts of all colleagues of the company, during the reporting period, the company's net profit attributable to shareholders of listed companies is expected to increase by 15%-25% compared with the same period of the previous ye.
The 2021 annual report shows that Tofflon is a comprehensive pharmaceutical equipment service provider that provides global pharmaceutical companies with overall solutions for pharmaceutical processes, core equipment and system engineeri.
After 28 years of hard work, more than 10,000 sets of pharmaceutical equipment and pharmaceutical manufacturing systems have served more than 2,000 global pharmaceutical companies in more than 40 countries and regions around the wor.
The company's main business is divided into three major sectors, namely pharmaceutical equipment sector, medical technology and technology sector, food equipment engineering sect.
As of the close on July 11, Tofflon closed at 33 yuan, down 83%, with a turnover rate of 51%, a trading volume of 65,600 lots, and a turnover of 219 million yu.
In terms of capital flow data, on July 11, the net outflow of main funds was 7649 million yuan, the net outflow of hot funds was 7398 million yuan, and the net inflow of retail funds was 5047 million yu.
It is worth mentioning that after Tofflon released the pre-announcement of its results for the first half of 2022, many institutions paid attenti.
Among them, Minsheng Securities released a research report on July 12, raising Tofflon's rating, and the rating was adjusted from "prudent recommendation" to "recommende.
Guosheng Securities gave Tofflon a rati.
It believes that the short-term impact of the epidemic will not constitute a restrictive factor on the company's annual performance, and Q3 is expected to usher in a full recovery; in the long run, the company is a platform supplier of domestic pharmaceutical equipment and consumabl.
Significant competitive advanta.
The agency said that it is optimistic about the company's firm strategy and forward-looking layo.
Taking advantage of the industry's momentum, the future can be expect.
1) Product perspective: The layout of equipment + consumables is complete, the equipment is the basic disk, and the consumables are expected to release increments in the future; 2) Rich customers: 30 years of deep cultivation in the pharmaceutical machine industry, with the help of rich customer resources, the trial and sales of products can be easily realized; 3 ) Internationalization: 11 new subsidiaries have been established in overseas countries and regions, and the CAGR of overseas revenue from 2015 to 2021 is 2
According to incomplete statistics, in the past 6 months, a total of 12 institutions of Tofflon have made predictions on its 2022 annual performan.
Among them, 5 institutions "buy", 3 institutions "increase", 2 institutions "recommend", 1 institution "prudently increase", and 1 institution "strongly recommend.
The target price forecast is 440 yu.
As of today's close, Tofflon's stock price fell 65%, with a turnover of 466 million, a turnover rate of 47%, and a price-earnings (TTM) of 28
